



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

	EN DIC DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
APPLICATION NO.	FILING DATE 02/26/2002	J. P. Bourguignon	37522-1001C2	3397
10/087,011			EXAMINER	
25710	7590 06/29/2004 ΛΕΥΕR, LLP		BORIN, MICHAEL L	
FOUR EMBA	RCADERO CENTER		ART UNIT	PAPER NUMBER
SUITE 400 SAN FRANC	ISCO, CA 94111		1631	
			DATE MAILED: 06/29/200	4

Please find below and/or attached an Office communication concerning this application or proceeding.

\
- K
35
Dai
~

Office Action Summary

Application No.	Applicant(s)	
10/087,011	BOURGUIGNON, J. P.	
Examiner	Art Unit	
Michael Borin	1631	

IVIICIAE	
The MAILING DATE of this communication appears on Period for Reply	
A SHORTENED STATUTORY PERIOD FOR REPLY IS SETHE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the If NO period for reply is specified above, the maximum statutory period will apply are Failure to reply within the set or extended period for reply will, by statute, cause the Any reply received by the Office later than three months after the mailing date of this earned patent term adjustment. See 37 CFR 1.704(b).	statutory minimum of thirty (30) days will be considered timely. In the mailing date of this communication. In the mailing date of this communication. In the mailing date of this communication.
Status	
1) Responsive to communication(s) filed on 2a) This action is FINAL . 2b) This action is 3) Since this application is in condition for allowance exceeds closed in accordance with the practice under <i>Ex parte</i> .	ept for formal matters, prosecution as to the merits is
Disposition of Claims	
4) Claim(s) 2-30 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 2-30 are subject to restriction and/or election	
Application Papers	
9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted of accepted to accepted of accepted of accepted to accepted of ac	(s) be held in abeyance. See 37 CFR 1.85(a). equired if the drawing(s) is objected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119	
12) Acknowledgment is made of a claim for foreign priority a) All b) Some * c) None of: 1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 3. Copies of the certified copies of the priority documents have application from the International Bureau (PCT * See the attached detailed Office action for a list of the	been received. been received in Application No cuments have been received in this National Stage Rule 17.2(a)).
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary (PTO-413) Paper No(s)/Mail Date 5) Notice of Informal Patent Application (PTO-152) 6) Other:

Serial Number: 10/087011

Art Unit: 1631

Part III DETAILED ACTION

Claims 2-30 are currently pending.

It is noted that claims 2-13 are in "use" format. For the purposes of the restriction requirement the claims are addressed as drawn to method of use.

Also, it is noted that claims 3-13 are improperly dependent on now canceled claim 1.

Restriction Requirement

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claims 2-13, drawn to method of making a medicament.
- II. Claims 14,17,19-26 drawn to method for influence on glutamate receptor-controlled cells.
- III. Claims 14, 17-26 drawn to method for influence on NMDA receptorcontrolled cells.
- IV. Claims 27--30 drawn to method for treatment of brain condition.

The inventions are distinct, each from the other because of the following reasons:

Inventions I-IV are related as independent and/or patentably distinct methods.

These methods either have different modes of operation (e.g., Group I vs Groups II-IV), or different functions (e.g., Group IV vs Groups II,III), or they have different

Page 3

Serial Number: 10/087011

Art Unit: 1631

effects (e.g., Group II vs Group III). A reference teaching, e.g., method of making

of pharmaceutical will not necessarily teach mechanism of receptor interaction of

such pharmaceutical or particular method of treatment.

Because these inventions are distinct for the reasons given above and have

acquired a separate status in the art because of their recognized divergent subject

matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the response to this requirement to be complete must

include an election of the invention to be examined even though the requirement be

traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected

invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if

one or more of the currently named inventors is no longer an inventor of at least one

claim remaining in the application. Any amendment of inventorship must be

accompanied by a diligently-filed petition under 37 CFR 1.48(b) and by the fee

required under 37 CFR 1.17(h).

Serial Number: 10/087011

Art Unit: 1631

Species Requirement

Election of species should be required prior to a search on the merits in all applications containing both species claims and generic or Markush claims.(MPEP 808.01(a))

Upon election of any single one of the Groups from above the following election of species is hereby required for the initial search for examination on merits:

The claims of Groups are generic to a plurality of disclosed patentably distinct species of antagonists, such as those listed in claims 6 or 19, that require a burdensome classification, and/or bibliographic, manual and computer searches. Accordingly, regardless of which group is elected, Applicant is required under 35 U.S.C. 121 to elect a single disclosed species (i.e., a single compound), even though the requirement is traversed.

Further, if Group IV is elected, applicant is requested to elect an excitatory effect from those listed in claim 27.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable

Page 5

Serial Number: 10/087011

Art Unit: 1631

over the prior art, the evidence or admission may be used in a rejection under 35

U.S.C. 103(a) of the other invention.

To be complete, a response to the election of species requirement should

include a proper election along with a listing of all claims readable thereon, including

any claims subsequently added. MPEP 809.02(a).

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Michael Borin whose telephone number is (571) 272-

0713. Dr. Borin can normally be reached between the hours of 8:30 A.M. to 5:00

P.M. EST Monday to Friday. If attempts to reach the examiner by telephone are

unsuccessful, the examiner's supervisor, Mr. Michael Woodward, can be reached on

(571) 272-0722.

Any inquiry of a general nature or relating the status of this application should

be directed to the Group receptionist whose telephone number is (571) 272-0549.

June 24, 2004

mlb